CANDI & UMASS: Pilot Study for Children with Fragile X Syndrome

The Child and Adolescent NeuroDevelopment Initiative (CANDI) at the University of Massachusetts Medical School is conducting a pilot research study on Fragile X syndrome, sponsored by Fulcrum Therapeutics. The goal of this study is to test new ways of measuring results in Fragile X clinical trials.

Eligible participants will have 3 study visits — 2 at the clinic and 1 at home.

The first clinic visit involves an assessment that will cover language ability, physical health, and medical history. The second clinic visit and the home visit involve the collection of blood, hair and cheek swab samples.

Participants will be compensated for time and travel.

Eligibility

Children ages 3 to 12 with a Fragile X diagnosis or who are typically developing

To Learn More, Please Contact:

Child and Adolescent NeuroDevelopment Initiative
University of Massachusetts Medical School
55 Lake Ave. North S3-301
Worcester, MA 01655
774-455-4100 OR
ChildResearch@umassmed.edu